AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte Post author:Sam Post published:October 30, 2017 Post category:BioPharma Astra and Incyte are pushing forward on the development of immunotherapy combination treatments. Source: BioSpace You Might Also Like MediWound Announces Changes To Its Board Of Directors May 17, 2017 CRO Giant PAREXEL Explores $4 Billion Sale, Stock Jumps May 8, 2017 Antibe Therapeutics Announces Closing Of Public Offering June 20, 2017